Gilead Sciences Inc (GILD)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 691,000 | 176,000 | 1,538,000 | 1,073,000 | 6,859,000 | 7,237,000 | 7,351,000 | 7,266,000 | 5,814,000 | 4,542,000 | 5,548,000 | 5,862,000 | 8,278,000 | 9,333,000 | 6,720,000 | 1,930,000 | 1,669,000 | 1,756,000 | -570,000 | 4,813,000 |
| Revenue (ttm) | US$ in thousands | 28,749,000 | 28,295,000 | 27,800,000 | 27,450,000 | 27,116,000 | 27,390,000 | 27,382,000 | 27,043,000 | 27,281,000 | 27,136,000 | 27,515,000 | 27,472,000 | 27,305,000 | 27,482,000 | 26,638,000 | 25,564,000 | 24,689,000 | 23,147,000 | 22,174,000 | 22,716,000 |
| Pretax margin | 2.40% | 0.62% | 5.53% | 3.91% | 25.30% | 26.42% | 26.85% | 26.87% | 21.31% | 16.74% | 20.16% | 21.34% | 30.32% | 33.96% | 25.23% | 7.55% | 6.76% | 7.59% | -2.57% | 21.19% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $691,000K ÷ $28,749,000K
= 2.40%
The pretax margin of Gilead Sciences Inc has fluctuated over the period under review. It started at a strong level of 21.19% in March 2020, but then took a sharp downturn to -2.57% by June 2020, indicating a period of financial challenge. The company managed to improve its performance, reaching 7.59% and 6.76% in the following quarters.
There was a notable recovery in the pretax margin in the first half of 2021, with percentages above 25% in June and September. This positive trend continued over the next few quarters, with the pretax margin consistently above 20%, indicating improved profitability.
However, towards the end of 2023 and into 2024, there was a decline in the pretax margin, dropping to as low as 0.62% in September 2024. This signals a potential decrease in profitability or increasing expenses relative to revenues during that period.
In conclusion, Gilead Sciences Inc has shown varying levels of pretax margin over the years, with periods of significant improvement followed by some decline. It is important for the company to closely monitor and manage its operating expenses and revenue generation to sustain profitability and financial performance in the future.
Peer comparison
Dec 31, 2024